Objectives: To evaluate bactericidal activity of PPI-0903M and in vitro testing parameters for this compound.
Introduction
PPI-0903 (formerly TAK-599) is a water-soluble prodrug of PPI-0903M (T-91825), a new generation semi-synthetic N-phosphono cephalosporin. When PPI-0903 is administered to animals, it converts to PPI-0903M upon hydrolysis of the phosphonate group. Preliminary in vitro studies demonstrated that PPI-0903M was very active against many clinically important bacterial pathogens, including streptococci (b-haemolytic, viridans group and Streptococcus pneumoniae), staphylococci (Staphylococcus aureus and coagulase-negative species), Haemophilus influenzae and Moraxella catarrhalis among others. PPI-0903M activity against these pathogens was similar to that demonstrated by other new anti-methicillin-resistant S. aureus (MRSA) cephalosporins. [1] [2] [3] [4] [5] [6] Moreover, PPI-0903M showed potent activity against multidrug-resistant Gram-positive pathogens that may cause both community-acquired and hospital-acquired infections, especially MRSA and penicillin-resistant S. pneumoniae. In various animal models, PPI-0903 has demonstrated excellent activities against MRSA and vancomycin-intermediate S. aureus (VISA). 6 Although a number of new agents have recently become available to treat infections caused by resistant Gram-positive organisms, all these agents (including daptomycin, linezolid and quinupristin/dalfopristin) lack activity against common Gramnegative pathogens, necessitating combination therapy for empirical treatment of many serious infections. There is a clinical need for a new broad-spectrum antimicrobial that covers both resistant Gram-positive and Gram-negative pathogens. PPI-0903 is currently being developed as a parenteral antimicrobial agent for the treatment of serious infections. 6 Quantitative colony counts were performed on the starting inoculum. The MBC was defined as the lowest concentration of PPI-0903M that killed ‡99.9% of the starting test inoculum. 9 Seventeen strains (six S. aureus, two Staphylococcus epidermidis, four S. pneumoniae, and one each of H. influenzae, E. coli, Klebsiella pneumoniae, Enterobacter cloacae and Serratia marcescens) were tested by the kill-curve methodology to again evaluate the bactericidal activity of PPI-0903M. Bacterial kill curves were performed in Mueller-Hinton broth (MHB) for all isolates except S. pneumoniae (MHB supplemented with 2-5% lysed horse blood) and H. influenzae (Haemophilus Test Medium broth). PPI-0903M activity was tested at timed intervals of 0, 4, 8 and 24 h at 1·, 2·, 4· and 8· MIC. 9 Broth microdilution MIC results for 15 strains (in triplicate) were compared with the standard, reference method after modifying broth pH (5.0, 6.0 and 8.0), incubation environments (5% CO 2 and anaerobic), inoculum concentration (5 · 10 3 and 10 7 cfu/mL), Ca 2+ content (trace and 50 mg/L), medium supplements (lysed horse blood and HTM) and human serum concentrations in the test broth (5, 10 and 50%).
Optimal disc content was assessed by testing seven reference strains with five PPI-0903M disc concentrations (5, 10, 30, 50 and 100 mg). The strains tested in this experiment were: S. aureus ATCC 25923 and 29213, E. faecalis ATCC 29212, S. pneumoniae ATCC 49619, E. coli ATCC 25922, P. aeruginosa ATCC 27853 and E. faecium 89-736D. The disc diffusion tests were performed according to CLSI/NCCLS methods.
10 Ceftriaxone and cefepime were tested concurrently as control agents of the same antimicrobial class.
Results
PPI-0903M exhibited bactericidal activity at or one log 2 dilution above the MIC for 86.4% of tested organisms and 90% of strains had an MBC/MIC ratio of £4 (preferred ratios). The majority of isolates with an MBC/MIC ratio >4 (6 of 11) were penicillinresistant S. pneumoniae (Table 1 ). Kill-curve kinetic studies confirmed the findings observed using MBC determinations for PPI-0903M (Table 2) . Bactericidal ( ‡3 log 10 cfu/mL reductions) action was noted for PPI-0903M at all multiples of the reference MIC tested (2·, 4· and 8·) against 12 of 17 strains (70.6%) tested. Three strains showed bactericidal activity only at 8· MIC (two oxacillin-resistant S. aureus) or at 4· and 8· MIC (S. aureus ATCC 25923 ). In addition, a reduction of only 2 log 10 cfu/mL after 24 h of incubation was noted for two S. pneumoniae strains, one penicillin-susceptible (MIC 0.06 mg/L) and one penicillinresistant strain (MIC 4 mg/L; Table 2 ). PPI-0903M was bactericidal versus all Enterobacteriaceae (including one S. marcescens) and H. influenzae strains tested. Table 3 summarizes the results from 15 organisms tested against PPI-0903M using 11 variations of the NCCLS methods. Only 16 (9.7%) MICs among 165 results varied by more than 4-fold when compared with the baseline, reference PPI-0903M MIC. One test condition (medium pH 5.0) was responsible for nine of 16 significant variations; results that were markedly lower than baseline MICs due to suboptimal growth concentrations or possible instability of PPI-0903M under acidic conditions. No significant increase in MICs (>1 log 2 dilution) was detected using MHB supplemented with three human serum concentrations (5, 10 and 50%) and nine organisms representing the streptococci, Enterobacteriaceae, non-fermentative Gram-negative bacilli and the staphylococci (Table 4) .
Susceptible Gram-positive QC strains all had PPI-0903M zone diameters of >20 mm for the 10 to 100 mg disc concentrations, and a corresponding MIC of £0.5 mg/L (Figure 1) . Maximum zone diameter differences (10 mm) between possible PPI-0903M-resistant strains (example: E. faecium) and susceptible species were achieved with PPI-0903M disc concentrations of 10 or 30 mg. Based on the results from this pilot experiment, the 10 mg disc content would be recommended for potential correlation of MIC breakpoints of £1-4 mg/L.
Discussion
PPI-0903M has demonstrated enhanced activity against resistant Gram-positive cocci and similar in vitro activity against common Gram-negative pathogens when compared with broad-spectrum cephalosporins.
5 PPI-0903M is very active against many clinically important bacterial pathogens, especially streptococci (bhaemolytic, viridans group and pneumococci), staphylococci [S. aureus and coagulase-negative staphylococci (CoNS)], H. influenzae and M. catarrhalis. PPI-0903M in vitro activity against these pathogens is similar or more potent when compared with other described anti-MRSA cephalosporins. [2] [3] [4] Moreover, PPI-0903M exhibited activity against several multidrug-resistant Grampositive pathogens that may cause both community-acquired and nosocomial infections, including MRSA and penicillin-resistant S. pneumoniae. 5 This spectrum of activity distinguishes PPI-0903 from currently available b-lactams and suggests that PPI-0903 has potential for use in the treatment of bacterial infections in the hospital environment. The prodrug, PPI-0903, is currently under Phase I clinical evaluation and has the potential to be a unique addition to the well-established, safe cephalosporin class.
In this study, PPI-0903M showed bactericidal activity against a wide range of tested species with MBC values near the measured MIC. Most importantly, PPI-0903M has demonstrated bactericidal activity against MRSA. PPI-0903M MIC results were very stable across numerous susceptibility test technical variations and human serum proteins did not adversely influence activity. The standard CLSI method can be easily applied to in vitro susceptibility testing of PPI-0903M. Further evaluations should be performed to establish the clinical role of this promising new generation anti-MRSA cephalosporin.
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